Anti-CLEC4C Antibody, clone 2O23 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

KLH-conjugated linear peptide corresponding to 22 amino acids from the N-terminal extracellular domain of human CLEC4C.

Quality Control Testing

Evaluated by Western Blotting in K-562 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected CLEC4C in K-562 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CLEC4C in lysate from human lymph node tissue and human tonsil tissue.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected CLEC4C in human tonsil tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound with CLEC4C peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

C-type lectin domain family 4 member C (UniProt: Q8WTT0; also known as Blood dendritic cell antigen 2 (BDCA-2), C-type lectin superfamily member 7, Dendritic lectin, CD303) is encoded by the CLEC4C (also known as BDCA2, CLECSF11, CLECSF7, DLEC, HECL) gene (Gene ID: 170482) in human. C-type lectin domain family 4 member C (CLEC4C) is a type II transmembrane glycoprotein belonging to the C-type lectin superfamily. It contains a carbohydrate recognition domain that facilitates binding to asialo-galactosyl-oligosaccharides. CLEC4C is predominantly expressed on plasmacytoid dendritic cells (pDCs), making it a highly specific marker for these cells. Its distribution is restricted to humans and plays a critical role in antigen capture and immune regulation. CLEC4C acts as an inhibitory receptor on pDCs by suppressing the production of type I interferons (IFN- /β) upon ligation. This mechanism is important for maintaining immune homeostasis and preventing excessive inflammatory responses. CLEC4C is involved in pathways such as the innate immune system and CLEC7A (Dectin-1) signaling, which are central to host defense against infections and immune regulation. Dysregulation of CLEC4C has been associated with autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis, where impaired CLEC4C signaling leads to excessive interferon production. Moreover, CLEC4C expression is altered in blastic plasmacytoid dendritic cell neoplasms (BPDCN), a rare and aggressive hematological malignancy, where it serves as a diagnostic marker. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Clone 2O23 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects CLEC4C. It targets an epitope within 22 amino acids from the N-terminal extracellular domain.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.